In the media

<p>Differences between tumours in male and female vinegar flies. Cayetano González, IRB Barcelona.</p>
22 Aug 2019 -

The newspapers Público and El Punt Avui,and the TV channel La Sexta, among other media, have reported on a recent study headed by Cayetano González, ICREA researcher at IRB Barcelona. Using the vinegar fly, Drosophila melanogaster, this study has identified possible regulators of the differences in tumours associated with the sex of an individual. Published in Science Advances, the study compares the brain tumours of male and female flies at the molecular level and identifies the protein responsible for the different degrees of aggressiveness. Understanding the molecular bases of the differences in the incidence of cancer and survival between men and women is crucial if specific and more...

<p>Interaction of the androgen receptor and chaperone Hsp70 (in red) inside the cell. Blue indicates cell nuclei. Xavier Salvatella, IRB Barcelona.</p>
14 Aug 2019 -

The radio station COPE, the newspaper ABC, RTVE and the scientific news agency SINC, among other media, have echoed news about a study led by Xavier Salvatella, head of the Molecular Biophysics Laboratory at IRB Barcelona. This study indicates that chaperone protein Hps70 could be an attractive therapeutic target for the treatment of Kennedy’s disease, a rare neuromuscular disorder, as well as castration-resistant prostate cancer.

Link to COPE

Link to ABC 

...

<p>The escape room “The #MetastasisChallenge against the clock” organised by IRB Barcelona.</p>
29 Jul 2019 -

TVE, the local TV channel Betevé and the newspaper La Vanguardia, among other media, have echoed on news about an escape room, “The #MetastasisChallenge against the clock”, organised by IRB Barcelona. In this game, participants have to solve a scientific puzzle in a real research lab. The proceeds from this activity will go to the #MetastasisChallenge, IRB Barcelona’s fundraising campaign in support of biomedical research into this disease.

Link to TVE

Link to Betevé

Link...

<p>Structure of a blood vessel. Raquel Batlle, IRB Barcelona.</p>
25 Jul 2019 -

RAC1, La Sexta and the newspapers La Vanguardia and ABC, among other media, have echoed on news of a study done by researchers of IRB Barcelona that has demonstrated that the p38 protein regulates the formation of new blood vessels in tumours. A greater understanding of how the development of new blood vessels is regulated may help to improve chemotherapy treatments for cancer. 

Link to RAC1 

Link to ...

<p>Clara Campàs, founding partner of Asabys Partners, Salvador Aznar-Benitah and Valerie Vanhooren, founders of Ona Therapeutics, and Sergio Pérez, director of Sabadell Venture Capital</p>
22 Jul 2019 -

The weekly supplement Dinero of La Vanguardia has published an article about Ona Therapeutics, the spin-off created by IRB Barcelona, ICREA and the researchers Salvador Aznar-Benitah and Valerie Vanhooren, with funding from Sabadell Asabys. Based on results published by Aznar in the journal Nature in 2017, the company aims to find a new treatment for metastatic cancer. “We found that the cells that give rise to metastasis are “addicted” to fats, and we envisaged developing a product, an antibody, that can block the protein responsible for fat uptake in these cells and thus combat their proliferation,” explains the researcher.

16 Jul 2019 -

L’Econòmic, the weekly supplement if the local newspaper El Punt Avui, has pinpointed Ona Therapeutics, the new spin-off from IRB Barcelona, as one of the ten Catalan start-ups with greatest projection. The company, which was founded by IRB Barcelona, ICREA, and the researchers Salvador Aznar Benitah and Valerie Vanhooren, with funding from Sabadell Asabys, focuses on the development of a new drug for the treatment of metastatic cancer.

 

Link to L’Econòmic

<p>Proliferative and invasive capacity of tumour cells (centre) compared to normal cells (left) and effect of TRAMETINIB treatment, which reduces the invasive capacity and tumoural load (right). Marco Milán, IRB Barcelona.</p>
11 Jul 2019 -

The programme El Matí, broadcasted on Catalunya Ràdio, and the newspapers La Vanguardia and El Punt Avui, among other media, have echoed on a study led by Marco Milán, head of the Development and Growth Control Laboratory at IRB Barcelona. This study reports on the team’s success in selectively eliminating cells that express the oncogene RAS. This oncogene is activated in 30% of humans cancers, and no effective inhibitors of this protein had been identified to date.

Link to...

<p>Valentina Maria Zinna, Salvador Aznar Benitah, Patrick Welz and Inés Marín Guillén, IRB Barcelona.</p>
31 May 2019 -

The newspapers La Vanguardia, Ara, and ABC, among other media, have echoed news of the publication of two studies in Cell by Salvador Aznar Benitah, ICREA researcher at IRB Barcelona, done in collaboration with the University of California, Irvine (USA). The research concludes that in mice with an impaired central clock, which is located in the brain, each tissue knows the time and is able to respond to changes in light that occur between the day and night.

Link to La Vanguardia

Link to...

<p>Clara Campàs, founding partner of Asabys Partners, Salvador Aznar-Benitah and Valerie Vanhooren, founders of Ona Therapeutics, and Sergio Pérez, director of Sabadell Venture Capital</p>
23 May 2019 -

La Vanguardia and Expansión Catalunya, among other media, have devoted an articleto Ona Therapeutics, the new IRB Barcelona spin-off that has completed a seed financing round of 1.5 million euros, invested entirely by Sabadell Asabys. With this injection of capital, the spin-off created by IRB Barcelona, ICREA and the researchers Salvador Aznar Benitah and Valerie Vanhooren, will start up activity with the development of a new drug for the treatment of metastatic cancer.

Link to La Vanguardia

Link to ...

<p>Antonio Zorzano and his team at the Complex Metabolic Diseases and Mitochondria Lab have participated in this study. IRB Barcelona.</p>
6 May 2019 -

La Vanguardia and La Sexta, among other media, have published an article on research headed by Antonio Zorzano, head of the Complex Metabolic Diseases and Mitochondria Lab at IRB Barcelona, which has identified a protein that protects against non-alcoholic fatty liver. “Mitofusin 2 emerges as a possible therapeutic target to combat fatty liver, a disease for which there is currently no treatment,” says the scientist.

The study has also been recommended by F1000 Prime.

Link to...